Astion Pharma A/S Report issue

For profit Phase 2 Phase 3
Founded: Skovlunde Denmark (1992)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2006
NCT00625521
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

azelaic acid (azelex) (1 trial)

Drugs in Phase 2 Trials (1)

asf 1096 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 3)

Dermatitis, Seborrheic (Phase 3)

Lupus Erythematosus, Discoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2